Emergent Bio (EBS) Issues Encouraging Update on TRU-016 Phase 1b in CLL ... StreetInsider.com (subscription) Emergent Biosolutions (NYSE: EBS) announced preliminary results from a Phase 1b single-arm, open-label study evaluating the safety and efficacy of otlertuzumab (TRU-016) in combination with rituximab in people with previously untreated chronic ... |
